CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Lycia Therapeutics Closes At $70 Million in Series B Financing Round

Life Sciences Review Life Sciences Review | Tuesday, September 21, 2021
Tweet

Lycia Therapeutics has completed a $70 million fundraising round, intending to develop novel targeted therapeutics based on its LYTAC protein degradation technology.


FREMONT, CA: Lycia Therapeutics, Inc. has closed at an oversubscribed $70 million Series B financing. Redmile Group led the round, with new investors Cowen Healthcare Investments, Invus, RTW Investments, LP, Eli Lilly and Company, and Alexandria Venture Investments, joining the round.


Lycia intends to leverage its recent $105 million in funding, which includes a Series B raise and a $35 million upfront payment from Lilly as part of the agreement, to advance its own undisclosed LYTAC degrader discovery pipeline.


“We’ve made significant progress since our Series A last year advancing our LYTAC platform, building our team, and forging a key strategic partnership with Lilly to further expand the opportunity of our technology to address unmet patient needs,” said Aetna Wun Trombley, Ph.D., President and CEO of Lycia. “We look forward to leveraging our recent $105 million capital influx to continue this momentum and advance our discovery pipeline of novel LYTAC degraders toward the clinic. 


Were thrilled to welcome Redmile and our other new investors and are grateful for Versants continued support.”


Lycia targets the untapped extracellular proteome, including cell surface receptors and secreted proteins, using its next-generation degradation method. The company's LYTAC (lysosomal targeting chimaeras) platform can be used to a variety of treatment modalities, including antibodies and small compounds, and has the potential to block numerous targets previously thought to be intractable across a wide range of therapeutic areas and disorders.


“Lycia’s focus on the untapped extracellular proteome and the potential to leverage the LYTAC platform across therapeutic modalities, including small molecules and antibodies, has the potential to transform the protein degradation field,” said Clare Ozawa, Ph.D., Managing Director with Versant Ventures and a Director on Lycia's Board. “We are very pleased with Lycia's progress since its founding and look forward to working with Redmile and the rest of this high-quality investor syndicate on the company's next stage of growth.”


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/lycia-therapeutics-closes-at-70-million-in-series-b-financing-round-nwid-570.html